This article is more than 5 years old. Information may no longer be current.

Meet us in Munich: Cardiology Today prepares for ESC 2012

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Cardiology Today and Cardiology Today Intervention editors have already landed in Munich in preparation for one of the year’s biggest events in cardiology — the European Society of Cardiology Congress 2012.

With more than 30,000 registered participants, the conference is expected to be the largest cardiology conference in the world.

Deepak L. Bhatt

This year, the conference’s theme highlights the importance of the synergistic relationship between basic science and clinical medicine.

“Only through the concerted efforts of both disciplines can we continue to bring further improvements to patient care,” ESC president Michael Komajda, MD, said in a press release issued by the association. “By choosing translational science as its 2012 congress spotlight, the ESC is encouraging critical discussion of new techniques and their rapid transfer into clinical practice.”

Carl J. Pepine

This year’s congress will feature 5 days of scientific sessions, more than 4,000 presentations of new studies and updates from earlier landmark trials. In addition, there will 17 Hot Line presentations featuring the first results from major clinical trials, including:

• TRILOGY-ACS, which evaluated prasugrel vs. clopidodrel for patients with unstable angina/NSTEMI who are medically managed without revascularization.
• FAME II, which assessed fractional flow reserve-guided percutaneous coronary intervention plus optimal medical treatment compared with medical therapy alone in patients with stable CAD.
• PROTECT, which examined patient outcomes with zotarolimus-eluting stents (Endeavor, Medtronic) vs. sirolimus-eluting stents (Cypher, Cordis).

“TRILOGY-ACS will be an important trial, as it will help us understand the role of long-term dual antiplatelet therapy in the medical management of ACS,” Cardiology Today Intervention Chief Medical Editor Deepak L. Bhatt, MD, MPH, said in an interview. “The randomization of patients to prasugrel or clopidogrel should shed light on whether more potent antiplatelet therapy is useful in this setting.”

“FAME II will be the focus of much interest. While a press release had previously issued, now we will get to see the actual data in detail. My guess is that there will not be a reduction in ‘hard’ endpoints, such as death or MI. It will be interesting to see how cardiologists interpret the study,” he said.

Joao A.C. Lima

Data from PROTECT, IABP-SHOCK II, GARY, FAST-MI, ACCESS EUROPE, GRACE, ALTITUDE and more will also be presented.

The ESC Congress 2012 is occurring from Aug. 25 to 29. Visit Healio.com/Cardiology throughout the week to learn more about these results and see exclusive comment from experts, including Cardiology Today Chief Medical Editor Carl J. Pepine, MD, and Editorial Board member Joao A.C. Lima, MD, MBA.